BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations

Nearly 100 public, private partnerships including leading pharmaceutical companies and African institutes drive forward research into neglected diseases

SEATTLE--()--BIO Ventures for Global Health (BVGH) today released its second compilation of WIPO Re:Search collaboration stories featuring partnerships accelerating neglected disease research. WIPO Re:Search, established by the World Intellectual Property Organization in partnership with BVGH and several leading pharmaceutical companies, brings scientists from academia and biopharmaceutical companies together to develop new therapies for diseases centered in developing nations. BVGH initiates these partnerships by identifying relevant research assets in pharmaceutical companies and matches them with academic researchers working on neglected tropical diseases. African researchers and institutions play a significant role in a number of the partnerships featured in this story book.

“This consortium is a particularly successful example of our work in the field of global health.”

Today’s report shows a jump in membership from 30 members in 2011 to 100 members across 27 countries in 2015, and from 13 research collaborations in 2012 to 95 collaborations this year. Takeda and Johnson & Johnson recently joined Pfizer, Novartis, GSK, Merck (MSD), Sanofi, Alnylam, Eisai, and Merck Serono Germany in contributing their resources to advance these neglected disease research programs. Currently, WIPO Re:Search has expanded into 18 different disease areas. Research focused on malaria, tuberculosis, Chagas disease and leishmaniosis represent the majority of these collaborations. These four diseases affect millions of people in Africa, Latin America and other developing countries. Almost half of the world’s population, 3.2 billion people, are at risk for malaria, which alone killed nearly 600,000 people in 2013. Tuberculosis is endemic in 146 countries and is the second leading killer among infectious diseases.

“Intellectual property is essential to spur innovation. WIPO Re:Search demonstrates that it can also be used as a tool to address debilitating diseases in developing countries,” stated Francis Gurry, Director General, WIPO. “This consortium is a particularly successful example of our work in the field of global health.”

“Many of these collaborations have already achieved important scientific milestones,” said Jennifer Dent, President of BVGH. “The scope of these partnerships has also expanded from sharing compounds to sharing cutting-edge technology, data, samples and scientific research expertise. This contributes to helping researchers in endemic countries advance their own product research and scientific capacity. The original aim of BVGH was to engage biopharmaceutical companies in solving global health challenges. WIPO Re:Search is an important effort in achieving this objective.”

The BVGH report highlights 26 specific, successful product development collaborations. It also features the impact of WIPO Re:Search on the University of Lagos in Nigeria.

About WIPO

The World Intellectual Property Organization (WIPO) is the global forum for intellectual property policy, services, information and cooperation. A specialized agency of the United Nations, WIPO assists its 188 member states in developing a balanced international IP legal framework to meet society's evolving needs. It provides business services for obtaining IP rights in multiple countries and resolving disputes. It delivers capacity-building programs to help developing countries benefit from using IP. And it provides free access to unique knowledge banks of IP information.

About BVGH

BIO Ventures for Global Health (BVGH) is a results-oriented nonprofit organization based in Seattle, Washington, USA whose mission is to engage private industry in global health initiatives. BVGH engages global health stakeholders in partnerships to accelerate the development of new drugs, vaccines, and diagnostics that address the unmet medical needs of the developing world. Working at the crossroads of the biopharmaceutical industry and global health, BVGH creates customized programs that fit the needs and capacity of partners and impact health in measurable ways.

Contacts

BVGH
President
Jennifer Dent
206-732-2131 (office)
650-228-4375 (cell)
jdent@bvgh.org

Recent Stories

RSS feed for BIO Ventures for Global Health